Anthem Biosciences Limited (ANTHEM) Stock Statistics & Valuation Metrics

Anthem Biosciences Limited has a market cap or net worth of ₹428.08B. The enterprise value is ₹424.66B.

Anthem Biosciences Limited has 563,195,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Anthem Biosciences Limited’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 16.06%.

The current PE Ratio of Anthem Biosciences Limited is 72.1. Anthem Biosciences Limited’s PEG ratio is 1.99.

In the last 12 months, Anthem Biosciences Limited had revenue of 21.24B and earned 5.92B in profits. Earnings per share was 10.55.

In the last 12 months, operating cash flow was 6.34B and capital expenditures -3.25B, giving a free cash flow of 3.09B billion.

Anthem Biosciences Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Anthem Biosciences Limited upcoming earnings date is Aug 19, 2026, Before Open (Confirmed).

Anthem Biosciences Limited as a current ratio of 5.54, with Debt / Equity ratio of 1.77%

In the past 12 months, Anthem Biosciences Limited has paid 2.32B in taxes.

Anthem Biosciences Limited EV to EBITDA ratio is 43.89, with an EV/FCF ratio of 51.85.

Anthem Biosciences Limited has ₹11.00B in cash and marketable securities with ₹1.10B in debt, giving a net cash position of ₹9.90B billion.

Gross margin is 46.91%, with operating margin of 32.94%, and net profit margin of 27.86%.

The average price target for Anthem Biosciences Limited is ₹802.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy